Gefitinib has also been proposed for the treatment of patients with locally advanced or metastatic NSCLC with EGFR-activating mutations (7), which targets the tyrosine kinase (TK) domain of EGFR, inhibiting the downstream signaling processes for growth and proliferation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.